从1,500,000教师库中查找（输入学校名称或教师姓名）
刘宝瑞老师介绍
姓名：刘宝瑞
研究方向：
1.恶性肿瘤靶向与个体化药物治疗；
2.中药抗肿瘤研究
联系方式（Email）：
baoruiliu@nju.edu.cn
代表性成果（专业成果、学术论文、学术专著等）：
最近2年来，发表SCI收录论文24篇，中文统计源论文63篇
1) Liu B, Yang M, Li R, Ding Y, Qian X, Yu L, Jiang X. The antitumor effect of novel docetaxel-loaded thermosensitive micelles. Eur J Pharm Biopharm. 2008;69(2):527-34. IF：3.185 ＊
2) Liu B, Wei J, Zou Z, Qian X, Nakamura T, Zhang W, Ding Y, Feng J, Yu L. Polymorphism of XRCC1 predicts overall survival of gastric cancer patients receiving oxaliplatin-based chemotherapy in Chinese population. Eur J Hum Genet 2007;15(10):1049-1053. IF: 3.697 ＊
3) Jia Wei, Zhengyun Zou, Xiaoping Qian, Yitao Ding， Li Xie, Jose Javier Sanchez, Yang Zhao, Jifeng Feng, Yang Ling, Yongping Liu, Lixia Yu, Rafael Rosel, Baorui Liu（通讯作者）. ERCC1 mRNA levels and survival of advanced gastric cancer patients treated with a modified FOLFOX regimen. Br J Cancer 2008; 98(8):1398-1402 IF：4.635＊
4) Cheng Z,Yiin H, Du J, Yue X, Qian X, Liu B（通讯作者）. Bilateral breast metastasis from small cell carcinoma of the ovary. J Clin Oncol 2008; 26(31):5129-30. IF：15.484＊
5) Wang T, Wei J,Qian X,Ding Y,Yu L, Liu B（通讯作者）. Gambogic acid, a potent inhibitor of survivin, reverses docetaxel resistance in gastric cancer cells. Cancer Lett. 2008;262(2):214-22. IF: 3.277 ＊
6) Liu B, Wang T, Qian X, Liu G, Yu L, Ding Y. Anticancer effect of tetrandrine on primary cancer cells isolated from ascites and pleural fluids. Cancer Lett. 2008;268(1):166-75. IF: 3.277
7) Li X,Li R,Qian X, Ding Y, Tu Y, Guo R,Hu Y,Jiang X, Guo W, Liu B（通讯作者）.Superior antitumor efficiency of cisplatin-loaded nanoparticles by intratumoral delivery with decreased tumor metabolism rate. Eur J Pharm Biopharm. 2008;70(3):726-34. IF：2.611
8) Wang L, Wei J, Qian X, Yin H, Zhao Y, Yu L, Wang T, Liu B（通讯作者）.ERCC1 and BRCA1 mRNA expression levels in metastatic malignant effusions is associated with chemosensitivity to cisplatin and/or docetaxel. BMC Cancer. 2008;8:97 IF：2.709
9) Liu B, Yang M, Li X, Qian X, Shen Z, Ding Y, Yu L. Enhanced efficiency of thermally targeted taxanes delivery in a human xenograft model of gastric cancer. J Pharm Sci. 2008;97(8):3170-81 IF: 2.238
10) Wang L, Liu B （通讯作者）, Wang T, Ding Y, Qian X,Zhao Y. Detection of Cell Free ERCC1 and TS mRNA in Malignant Effusions and its Association with anticancer drug sensitivity. Anticancer Research 2008;28(2A):1085-91 IF：1.414
11) Shen S, Xu Z, Qian XP,Ding YT,Yu LX , Liu BR（通讯作者） . RNA-electroporated CD40-activated B cells induce functional T-cell responses against HepG2 cells. Eur J Cancer Care (Engl). 2008 ;17(4):404-11. IF：1.038
12) Cheng ZX, Liu BR（通讯作者）, Qian XP, Ding YT, Hu WJ, Sun J, Yu LX. Proteomic analysis of anti-tumor effects by Rhizoma Paridis total saponin treatment in HepG2 cells. J Ethnopharmacol. 2008;120(2):129-37. IF：2.049
13) Qiu LX, Tang QY, Bai JL, Qian XP, Li RT, Liu BR, Zheng MH. Predictive value of thymidylate synthase expression in advanced colorectal cancer patients receiving fluoropyrimidine-based chemotherapy: evidence from 24 studies. Int J Cancer. 2008 ;123(10):2384-9. IF:4.555
14) Qiu LX, Li RT, Zhang JB, Zhong WZ, Bai JL, Liu BR, Zheng MH, Qian XP. The E-cadherin (CDH1) -160 C/A polymorphism and prostate cancer risk: a meta-analysis. Eur J Hum Genet.2009; 17(2):244-9. IF:4.003
15) Wei J, Liu B（通讯作者）,Wang L, Qian X, Ding Y, Yu L. Synergistic interaction between tetrandrine and chemotherapeutic agents and influence of tetrandrine on chemotherapeutic agent-associated genes in human gastric cancer cell lines. Cancer Chemother Pharmacol 2007, 60(5):703–711. IF: 2.363
16) Yang M, Ding Y, Zhang L, Qian X,Jiang X, Liu B（通讯作者）. Novel thermosensitive polymeric micelles for docetaxel delivery. J Biomed Mater Res A 2007, 81(4):847-857. IF: 2.497
17) Sun J, Liu BR （通讯作者）, Hu WJ, Yu LX, Qian XP. In vitro Anticancer Activity of Aqueous Extracts and Ethanol Extracts on Human Digestive Tumor Cell Lines. Phytother Res. 2007, 21(11):1102-1104. IF: 1.192
18) Zhang L, Yang M, Wang Q, Li Y, Guo R, Jiang X, Liu B. 10-Hydroxycamptothecin loaded nanoparticles: preparation and antitumor activity in mice. J Control Release. 2007, 119(2):153-162. IF: 4.012
19) Zhang LY, Guo, R Yang M, Jiang X, Liu B. Thermo and pH Dual-Responsive Nanoparticles for Anti-Cancer Drug Delivery. Adv Mater 2007, 19(19):2988–2992. IF: 7.896
20) Shen S, Xu Z, Qian X, Ding Y, Yu L, Liu B.（通讯作者）.Autogeneic RNA-electroporated CD40-Activated B Cells from Hepatocellular Carcinoma Patients induce CD8+ T Cell Responses Ex Vivo. Experimental Oncology，2007;29(2):137-143 IF：0.753
21) Wang TT, Qian XP, Liu BR（通讯作者）. Survivin:Potential role in diagnosis,prognosis and targeted therapy of gastric cancer. Wold J Gastroenterol 2007;13(20):2784-2790
22) Yang M, Ding Y, Huang Z, Qian X, Yu L, Liu B（通讯作者）. Preparation and charaterization of cisplatin-loaded thermosensitive micelle. Chinese J Inorg Chem, 2007, 23(2):205-210 IF: 0.583
23) Liu, BR. Relationship between beta-tubulin mRNA expression and sensitivity to docetaxel in malignant effusions from non small-cell lung cancer (NSCLC) and gastric cancer patients. BIOMEDICINE & PHARMACOTHERAPY. 2008,62(7):423-423. IF：1.418
24) J. Wei, B. Liu（通讯作者）, Z. Zou, X. Qian, W. Zhang and L. Yu. ERCC1 mRNA expression and XRCC1 polymorphism as predictive factors for overall survival in gastric cancer patients receiving platinum based chemotherapy. Journal of Clinical Oncology 2007;25(18S): 2512. IF: 13.598
主编著作3本：
《临床肿瘤学》2007 科学出版社 北京………………………
《恶性肿瘤精确诊断与治疗新技术》2007 江苏科技出版社 南京……
《现代肿瘤化疗手册》2000 世界图书出版西安公司 西安………
科研项目：题目之一：肿瘤抑制基因在胃癌发生早期及转移中的变化
来源：国家自然科学基金
批准号：39400060
起止年：1995.01~1997.12（已结题）
题目之二：B/RNA技术的建立及对肝癌细胞的杀伤作用
来源：国家自然科学基金
批准号：30471701
起止年：2005.01~2007.12（已结题）
题目之三：温敏多西紫杉醇纳米胶束的研制及在胃癌热靶向肿瘤中的评价
来源：国家自然科学基金
批准号：30670958
起止年：2007.01~2009.12（在研中）
题目之四：Tet-Ptx控释纳米微球的构建及对胃癌靶向治疗中的评价
来源：国家自然科学基金
批准号：30872471
起止年：2009.01~2011.12（在研中）
题目之五： 靶向抗肿瘤药物载体纳米技术平台的建立及相关研究
来源：江苏省医学重点人才项目
起止年：2008.01~2012.12（在研中）
题目之六：恶性肿瘤实时个体化疗－肿瘤转移灶药物预测分子的研究
来源：江苏省“六大人才高峰”项目A类
批准号：07-B-028
起止年：2008.01~2009.12（在研中）
题目之七：Tet-Ptx控释纳米微球的构建及对胃癌协同靶向治疗中的评价
来源：江苏省自然基金
批准号：BK2008064
起止年：2008.01~2010.12（在研中）
题目之八：消化系肿瘤药物基因组学/遗传学指导下肿瘤个体化疗的研究
来源：南京市卫生重点项目
批准号：ZKX05015
起止年：2006.01~2008.12（已结题）
研究方向：
1.恶性肿瘤靶向与个体化药物治疗；
2.中药抗肿瘤研究
联系方式（Email）：
baoruiliu@nju.edu.cn
代表性成果（专业成果、学术论文、学术专著等）：
最近2年来，发表SCI收录论文24篇，中文统计源论文63篇
1) Liu B, Yang M, Li R, Ding Y, Qian X, Yu L, Jiang X. The antitumor effect of novel docetaxel-loaded thermosensitive micelles. Eur J Pharm Biopharm. 2008;69(2):527-34. IF：3.185 ＊
2) Liu B, Wei J, Zou Z, Qian X, Nakamura T, Zhang W, Ding Y, Feng J, Yu L. Polymorphism of XRCC1 predicts overall survival of gastric cancer patients receiving oxaliplatin-based chemotherapy in Chinese population. Eur J Hum Genet 2007;15(10):1049-1053. IF: 3.697 ＊
3) Jia Wei, Zhengyun Zou, Xiaoping Qian, Yitao Ding， Li Xie, Jose Javier Sanchez, Yang Zhao, Jifeng Feng, Yang Ling, Yongping Liu, Lixia Yu, Rafael Rosel, Baorui Liu（通讯作者）. ERCC1 mRNA levels and survival of advanced gastric cancer patients treated with a modified FOLFOX regimen. Br J Cancer 2008; 98(8):1398-1402 IF：4.635＊
4) Cheng Z,Yiin H, Du J, Yue X, Qian X, Liu B（通讯作者）. Bilateral breast metastasis from small cell carcinoma of the ovary. J Clin Oncol 2008; 26(31):5129-30. IF：15.484＊
5) Wang T, Wei J,Qian X,Ding Y,Yu L, Liu B（通讯作者）. Gambogic acid, a potent inhibitor of survivin, reverses docetaxel resistance in gastric cancer cells. Cancer Lett. 2008;262(2):214-22. IF: 3.277 ＊
6) Liu B, Wang T, Qian X, Liu G, Yu L, Ding Y. Anticancer effect of tetrandrine on primary cancer cells isolated from ascites and pleural fluids. Cancer Lett. 2008;268(1):166-75. IF: 3.277
7) Li X,Li R,Qian X, Ding Y, Tu Y, Guo R,Hu Y,Jiang X, Guo W, Liu B（通讯作者）.Superior antitumor efficiency of cisplatin-loaded nanoparticles by intratumoral delivery with decreased tumor metabolism rate. Eur J Pharm Biopharm. 2008;70(3):726-34. IF：2.611
8) Wang L, Wei J, Qian X, Yin H, Zhao Y, Yu L, Wang T, Liu B（通讯作者）.ERCC1 and BRCA1 mRNA expression levels in metastatic malignant effusions is associated with chemosensitivity to cisplatin and/or docetaxel. BMC Cancer. 2008;8:97 IF：2.709
9) Liu B, Yang M, Li X, Qian X, Shen Z, Ding Y, Yu L. Enhanced efficiency of thermally targeted taxanes delivery in a human xenograft model of gastric cancer. J Pharm Sci. 2008;97(8):3170-81 IF: 2.238
10) Wang L, Liu B （通讯作者）, Wang T, Ding Y, Qian X,Zhao Y. Detection of Cell Free ERCC1 and TS mRNA in Malignant Effusions and its Association with anticancer drug sensitivity. Anticancer Research 2008;28(2A):1085-91 IF：1.414
11) Shen S, Xu Z, Qian XP,Ding YT,Yu LX , Liu BR（通讯作者） . RNA-electroporated CD40-activated B cells induce functional T-cell responses against HepG2 cells. Eur J Cancer Care (Engl). 2008 ;17(4):404-11. IF：1.038
12) Cheng ZX, Liu BR（通讯作者）, Qian XP, Ding YT, Hu WJ, Sun J, Yu LX. Proteomic analysis of anti-tumor effects by Rhizoma Paridis total saponin treatment in HepG2 cells. J Ethnopharmacol. 2008;120(2):129-37. IF：2.049
13) Qiu LX, Tang QY, Bai JL, Qian XP, Li RT, Liu BR, Zheng MH. Predictive value of thymidylate synthase expression in advanced colorectal cancer patients receiving fluoropyrimidine-based chemotherapy: evidence from 24 studies. Int J Cancer. 2008 ;123(10):2384-9. IF:4.555
14) Qiu LX, Li RT, Zhang JB, Zhong WZ, Bai JL, Liu BR, Zheng MH, Qian XP. The E-cadherin (CDH1) -160 C/A polymorphism and prostate cancer risk: a meta-analysis. Eur J Hum Genet.2009; 17(2):244-9. IF:4.003
15) Wei J, Liu B（通讯作者）,Wang L, Qian X, Ding Y, Yu L. Synergistic interaction between tetrandrine and chemotherapeutic agents and influence of tetrandrine on chemotherapeutic agent-associated genes in human gastric cancer cell lines. Cancer Chemother Pharmacol 2007, 60(5):703–711. IF: 2.363
16) Yang M, Ding Y, Zhang L, Qian X,Jiang X, Liu B（通讯作者）. Novel thermosensitive polymeric micelles for docetaxel delivery. J Biomed Mater Res A 2007, 81(4):847-857. IF: 2.497
17) Sun J, Liu BR （通讯作者）, Hu WJ, Yu LX, Qian XP. In vitro Anticancer Activity of Aqueous Extracts and Ethanol Extracts on Human Digestive Tumor Cell Lines. Phytother Res. 2007, 21(11):1102-1104. IF: 1.192
18) Zhang L, Yang M, Wang Q, Li Y, Guo R, Jiang X, Liu B. 10-Hydroxycamptothecin loaded nanoparticles: preparation and antitumor activity in mice. J Control Release. 2007, 119(2):153-162. IF: 4.012
19) Zhang LY, Guo, R Yang M, Jiang X, Liu B. Thermo and pH Dual-Responsive Nanoparticles for Anti-Cancer Drug Delivery. Adv Mater 2007, 19(19):2988–2992. IF: 7.896
20) Shen S, Xu Z, Qian X, Ding Y, Yu L, Liu B.（通讯作者）.Autogeneic RNA-electroporated CD40-Activated B Cells from Hepatocellular Carcinoma Patients induce CD8+ T Cell Responses Ex Vivo. Experimental Oncology，2007;29(2):137-143 IF：0.753
21) Wang TT, Qian XP, Liu BR（通讯作者）. Survivin:Potential role in diagnosis,prognosis and targeted therapy of gastric cancer. Wold J Gastroenterol 2007;13(20):2784-2790
22) Yang M, Ding Y, Huang Z, Qian X, Yu L, Liu B（通讯作者）. Preparation and charaterization of cisplatin-loaded thermosensitive micelle. Chinese J Inorg Chem, 2007, 23(2):205-210 IF: 0.583
23) Liu, BR. Relationship between beta-tubulin mRNA expression and sensitivity to docetaxel in malignant effusions from non small-cell lung cancer (NSCLC) and gastric cancer patients. BIOMEDICINE & PHARMACOTHERAPY. 2008,62(7):423-423. IF：1.418
24) J. Wei, B. Liu（通讯作者）, Z. Zou, X. Qian, W. Zhang and L. Yu. ERCC1 mRNA expression and XRCC1 polymorphism as predictive factors for overall survival in gastric cancer patients receiving platinum based chemotherapy. Journal of Clinical Oncology 2007;25(18S): 2512. IF: 13.598
主编著作3本：
《临床肿瘤学》2007 科学出版社 北京………………………
《恶性肿瘤精确诊断与治疗新技术》2007 江苏科技出版社 南京……
《现代肿瘤化疗手册》2000 世界图书出版西安公司 西安………
科研项目：题目之一：肿瘤抑制基因在胃癌发生早期及转移中的变化
来源：国家自然科学基金
批准号：39400060
起止年：1995.01~1997.12（已结题）
题目之二：B/RNA技术的建立及对肝癌细胞的杀伤作用
来源：国家自然科学基金
批准号：30471701
起止年：2005.01~2007.12（已结题）
题目之三：温敏多西紫杉醇纳米胶束的研制及在胃癌热靶向肿瘤中的评价
来源：国家自然科学基金
批准号：30670958
起止年：2007.01~2009.12（在研中）
题目之四：Tet-Ptx控释纳米微球的构建及对胃癌靶向治疗中的评价
来源：国家自然科学基金
批准号：30872471
起止年：2009.01~2011.12（在研中）
题目之五： 靶向抗肿瘤药物载体纳米技术平台的建立及相关研究
来源：江苏省医学重点人才项目
起止年：2008.01~2012.12（在研中）
题目之六：恶性肿瘤实时个体化疗－肿瘤转移灶药物预测分子的研究
来源：江苏省“六大人才高峰”项目A类
批准号：07-B-028
起止年：2008.01~2009.12（在研中）
题目之七：Tet-Ptx控释纳米微球的构建及对胃癌协同靶向治疗中的评价
来源：江苏省自然基金
批准号：BK2008064
起止年：2008.01~2010.12（在研中）
题目之八：消化系肿瘤药物基因组学/遗传学指导下肿瘤个体化疗的研究
来源：南京市卫生重点项目
批准号：ZKX05015
起止年：2006.01~2008.12（已结题）
刘宝瑞老师相关教学资源
- 南京大学教学资源
- 刘宝瑞老师课程教学资源
